Melanoma: Early Detection and Immunotherapy Treatment

When melanoma is caught early, the chance of surviving five years or more is over 99%. But if it spreads to other organs, that number drops to just 32%. This isn’t just a statistic-it’s the difference between living a full life and facing a life-threatening illness. Melanoma doesn’t always look like a dark, uneven mole. Sometimes it’s a tiny spot that doesn’t heal. Other times, it’s a streak under a fingernail or a new bump that grows slowly. The problem? Most people don’t know what to look for. And even doctors can miss it without the right tools.

How Melanoma Is Detected Today

The old way of checking for melanoma? A visual exam. A doctor looks at your skin, maybe uses a magnifying tool called a dermoscope. But studies show this method catches only 60-70% of melanomas. That means nearly 1 in 3 cases are missed. It’s not because doctors aren’t careful-it’s because melanoma can hide in strange places and look like harmless moles.

Now, new technologies are stepping in. One of the most promising is a handheld device called DermaSensor. Approved by the FDA in early 2024, it uses near-infrared light to scan skin lesions. It doesn’t need a specialist. A family doctor can use it after just 2-3 hours of training. In trials, 87% of primary care providers said it gave them more confidence in their diagnosis. But here’s the catch: its specificity is only 26-40%. That means it flags a lot of harmless spots as suspicious. More biopsies. More anxiety. More cost.

Then there’s AI. Not the kind you see in movies-this is real, trained on hundreds of thousands of real skin images. Systems like SegFusion from Northeastern University combine two AI models: one that outlines the exact shape of a mole, and another that decides if it’s cancerous. It hits 99% accuracy. On the ISIC 2020 dataset-where melanoma made up only 1.8% of images-it still performed flawlessly. Why? Because it didn’t just learn from what melanoma looks like. It learned how to isolate it from everything else.

Full-body scanners are another breakthrough. The iToBoS project, backed by 20 European research teams, can scan a person’s entire skin in six minutes. It maps every spot, tracks changes over time, and flags risks with explainable AI. That means the system doesn’t just say “cancer”-it shows the doctor exactly why it thinks so. This is huge. Doctors don’t trust black boxes. They need to understand the logic.

The Hidden Problem: Bias in AI

Here’s something no one talks about enough: most AI systems for skin cancer were trained mostly on light skin. A 2025 JAMA Dermatology study found these tools are 12-15% less accurate on darker skin tones. That’s not a small gap. It’s life or death. A dark spot on a Black patient might be melanoma. But if the AI doesn’t recognize it because it was never trained on that skin type, the patient gets sent home with a “probably harmless” label. And that’s deadly.

Some companies are fixing this. SegFusion and iToBoS now include diverse datasets. But many commercial tools still don’t. If you’re using an AI tool, ask: Was it tested on people with different skin tones? If the answer is no, it’s not reliable for everyone.

What’s Coming Next

Wearable patches are on the horizon. Researchers at Wake Forest built a battery-free, wireless patch that sticks to the skin. It measures electrical differences between healthy tissue and cancerous cells. In a small trial with 10 volunteers, it found clear differences. The next version will use conductive hydrogel to stick better. Imagine checking your skin at home every week-no clinic visit needed.

And it’s not just about images. The future is multimodal. Combining AI scans with bioimpedance, genetic markers, even blood tests. One study is already testing whether adding oxygen levels and blood pressure data improves AI predictions. If it works, a simple skin scan could be paired with a quick health profile to give a much clearer picture.

Immunotherapy: Turning the Body Against Cancer

If melanoma spreads, surgery isn’t enough. That’s where immunotherapy comes in. Before 2011, metastatic melanoma was almost always fatal. Now, it’s treatable. And in many cases, curable.

The first big breakthrough was ipilimumab, a drug that blocks a protein called CTLA-4. It woke up the immune system to attack cancer. Then came pembrolizumab and nivolumab-drugs that block PD-1. These were game-changers. Today, the standard is combination therapy: a PD-1 blocker plus a CTLA-4 blocker. This combo works better than either drug alone. In clinical trials, over half of patients with advanced melanoma saw their tumors shrink. Some disappeared completely.

Now, the next wave is here. Regeneron is testing a new combo: a PD-1 blocker with fianlimab, which targets LAG-3, another immune checkpoint. Early results show even deeper responses. And then there’s IMA203 PRAME cell therapy-a personalized treatment that trains a patient’s own immune cells to hunt melanoma. In Phase 1b, 56% of patients had no detectable cancer after treatment. It’s not approved yet, but the data is strong.

Immunotherapy isn’t perfect. Side effects can be serious: fatigue, rashes, even inflammation of the lungs or liver. But compared to chemotherapy? It’s a win. And for many, it means living years longer than anyone expected.

Real-World Challenges

These tools sound amazing. But getting them into clinics? That’s the hard part.

Integration takes time. Dermatology offices report needing 15-20 hours of training just to use one AI system. DermaSensor? Only 2-3 hours. But if the system doesn’t plug into your electronic health records, doctors won’t use it. And right now, 76% of providers say integration is a nightmare.

Then there’s cost. The FDA approves AI tools, but insurance doesn’t always cover them. Google Health pulled its AI tool from the market in late 2024 because reimbursement was too low. If doctors can’t get paid for using it, they won’t use it.

And there’s overdiagnosis. A 2025 study warned that screening too aggressively might catch tiny melanomas that would never harm anyone. More biopsies. More scars. More stress. The goal isn’t to find every single mole. It’s to find the dangerous ones-and leave the rest alone.

What You Can Do

You don’t need a high-tech scanner to save your life. Here’s what works right now:

• Check your skin monthly. Use the ABCDE rule: Asymmetry, Border irregularity, Color variation, Diameter over 6mm, Evolving size or shape.
• Don’t ignore spots that bleed, itch, or don’t heal.
• If you have a family history of melanoma or many moles, see a dermatologist yearly.
• Ask your doctor: Do you use any AI tools for skin checks? Are they tested on diverse skin tones?
• Protect your skin daily. UV exposure is the #1 cause. Wear sunscreen, hats, and avoid tanning beds.

Early detection saves lives. But detection alone isn’t enough. We need better tools, fairer AI, and access for everyone-not just those who can afford it.

The Future Is Here

By 2030, AI-assisted melanoma detection will likely be standard. Immunotherapy will keep improving. Survival rates will rise. But progress won’t be automatic. It needs investment. It needs diversity in data. It needs policy changes. And it needs patients to speak up.

This isn’t science fiction. It’s happening now. In Sydney, in Berlin, in Cleveland. In clinics using AI to spot cancer before it spreads. In labs designing patches that could one day be sold at pharmacies. In trials where patients are beating odds no one thought possible.

The message is simple: If you see something strange on your skin, don’t wait. And if you’re a doctor-ask: Is your tool helping everyone, or just some?